When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ALDR - Alder's eptinezumab shows treatment effect in late-stage migraine study
Alder BioPharmaceuticals Inc.
A new analysis of patient-reported outcomes from a Phase 3 clinical trial, PROMISE-2, evaluating Alder BioPharmaceuticals' (NASDAQ:ALDR) migraine prevention med eptinezumab confirmed its treatment benefit. The data are being presented at the American Academy of Neurology Annual Meeting in Philadelphia.
More news on: Alder BioPharmaceuticals, Inc., Healthcare stocks news,